Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NASDAQ: ARDX); Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI): Grabar Law Office is Investigating…

PHILADELPHIA , Oct. 05, 2026 (GLOBE NEWSWIRE) --

Anavex Life Sciences Corp. (NASDAQ: AVXL):

Grabar Law Office is investigating claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL).

What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Anavex breached their fiduciary duties owed to the Company and its shareholders.

Current Anavex Life Sciences Corp. (NASDAQ: AVXL) shareholders who have held Anavex shares since on or before November 26, 2025, are encouraged to visit https://grabarlaw.com/the-latest/anavex-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever.

What is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Anavex Life Sciences Corp. (NASDAQ: AVXL), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Anavex lacked adequate internal controls; (ii) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (iii) as a result, defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On May 6, 2026, Anavex filed a current report on Form 8-K with the United States Securities and Exchange Commission (“SEC”), allegedly stating that “[o]n April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors (the “Board”) of Anavex Life Sciences Corp. (the “Company”) terminated the employment of Christopher Missling, PhD as the Company’s Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.” On this news, the price of Anavex stock declined nearly 1%, according to the complaint.

Then, on May 11, 2026, after market hours, Anavex filed with the SEC a notification of late filing on Form 12b-25, allegedly stating that Anavex was “unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026,” due in part to Anavex’s internal review of “certain matters related to the termination of Dr. Missling.” On this news, the price of Anavex stock fell nearly 6%, according to the complaint.

Finally, on August 28, 2026, after market hours, Anavex filed with the SEC an amended annual report on Form 10-K/A for the fiscal year ended September 30, 2025, allegedly disclosing in part that “[a]s a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the “Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025,” and that Anavex’s “disclosure controls and procedures were not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting as described above.” That same day, Anavex allegedly filed with the SEC its quarterly reports for the periods ending March 31, 2026 and June 30, 2026, which both contained the following disclosure: “[f]ollowing the previously disclosed termination of our former CEO in April 2026, management has determined that our disclosure controls and procedures and our internal controls over financial reporting were not effective as of September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026.” On this news, the price of Anavex stock declined more than 6%, according to the complaint.

What Can You Do Now? If you are a current Anavex Life Sciences Corp. (NASDAQ: AVXL) shareholder who has held Anavex shares since on or before November 26, 2025, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/anavex-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call Joshua H. Grabar at 267-507-6085. Alternatively, if you purchased Anavex shares between November 26, 2025 and August 28, 2026, you can participate in the class action. #Anavex #AVXL $AVXL

Ardelyx, Inc. (NASDAQ: ARDX):

Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NASDAQ: ARDX).

What is The Investigation About? The investigation concerns whether certain officers and directors breached their fiduciary duties owed to the Company and its shareholders.
If you have held Ardelyx, Inc. (NASDAQ: ARDX) shares since on or before January 13, 2025, visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. Alternatively, investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive can participate in the class action.

What is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Ardelyx, Inc. (NASDAQ: ARDX), through certain of its officers, provided investors with material information concerning Ardelyx’s fiscal year 2026 revenue outlook for its two core drug products, XPHOZAH and IBSRELA, as well as their anticipated long-term growth. Defendants’ statements included, among other things, confidence in the Company's continued commercial growth and ability to execute its commercial strategy to overcome payer and patient-access barriers, and its ability to achieve its projected revenue guidance and long-term growth targets.

It is alleged that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Ardelyx’s securities at artificially inflated prices.

It is further alleged that the truth emerged after the market closed on August 6, 2026, when Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections.

What Can You Do Now? Current Ardelyx, Inc. (NASDAQ: ARDX) shareholders who have held Ardelyx shares since on or before January 13, 2025, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085. Alternatively, investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive can participate in the class action. #ARDX #Ardelyx $ARDX

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.

If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.

The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.

Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.

Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.

What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #AARD $AARD #Aardvark

GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI)

Grabar Law Office is investigating claims on behalf of shareholders of GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO).

What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/gpgi-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

What Is Alleged? It is alleged in a recently filed federal securities fraud class action complain that GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) defendants had materially overstated the value of Husky; (ii) Husky was not on track to achieve the revenue and Adjusted EBITDA targets provided in the proxy statement and such targets lacked a reasonable basis in objective fact; (iii) a primary motivation of the Husky Acquisition was to generate millions of dollars in fees for Resolute Holdings and the individual defendants, rather than to create long-term value for CompoSecure shareholders; and (iv) as a result of the above, defendants had materially misrepresented the business, prospects, and expected financial results of GPGI and Husky as a combined business.

What Can You Do Now? If you purchased GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI; CMPO) shares prior to November 3, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/gpgi-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. #GPGI $GPGI #CompoSecure $CMPO

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com